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of brain and spinal cord called as oligodendrocytes. Both genetic and environmental factors play roles inMS. One
of these genes is the killer-cell immunoglobulin-like receptor (KIR)which expressed on surface of natural killer cells
(NKs). These genes have loci (not locus) in human genome, so they inherit as haplotypes. The results of previous
studies show that different genes of KIRmay affect both susceptibility and resistance to such autoimmune disor-
ders that their pathogenesis inMS is still unclear. SinceNKs play key roles in immune tolerance,we intend to per-
form a meta-analysis for the correlation of KIR genes and MS. We used the software comprehensive meta-
analysis for data of totally 568 MS patients and 280 controls. Among the 14 genes of KIR in the human genome,
lack of KIR2DS1 is accompanied byMS. No KIR gene found to be a risk factor forMS. Further studies on othermol-
ecules of NKs like CD94 and NKG2a is suggested.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Multiple sclerosis
Killer cell immunoglobulin-like receptor
Meta-analysis1. Introduction
Multiple sclerosis (MS) is a disease in which we can recognize de-
struction of the myelin that is around nerve cells of brain and spinal
cord called as oligodendrocytes. Both genetic and environmental factors
play roles in MS [1–3]. It is better to say that infectious agents as an ex-
ample for environmental factors can increase the chance of developing
MS in the individuals those who are genetically susceptible for that [4].
Among the genes that have been found for the disease, human leuco-
cyte antigen (HLA) system is the most important one [5,6] and this sys-
tem has also some associations with other Auto immune diseases like
type 1 diabetes [7] and systemic lupus erythematosus (SLE) [8].
As we mentioned, infectious agents also play roles in this disease.
Many microbes like different viruses are known for their participating.
For instance Herpes virus family specially group four the Epstein-Barr
virus (EBV). There is a belief that the persons those who have not
been infected by this family of viruses, have lower chance to develop
MS than those who had these infections [5].
Different aspects of the immune system ofMS patients seem to have
functional problems; for example the increase in aggressive activity of
Th1, Th17 and T CD8+ or decrease in regulatory T cells activity and
also unusual function of B lymphocyte cells, Antibodies, complement
system and natural killer cells (NKs) [9].
Morphology wise, NKs are a kind of lymphocyte cells, however their
functions are in the innate immune system. These cells are the ﬁrst parthmadi).
. This is an open access article underof immune systemwhich defend the body against cancerous or infected
cells, but if they cannot be successful in performing their tasks, it can
cause a variety of problems like different types of cancers, infections,
immunodeﬁciency syndromes and even auto immune diseases. The
majority of NKs have cytotoxic effects of course just against cells with
impaired or without HLA class 1 molecules [10–13]. But on the other
hand, there are NKs called CD56bright which kill the activated T lympho-
cytes which their action is against the myelin surrounding nerve cells
[14]. In MS a reduction could be recognized in the amount of this kind
of NKs along with reduction of T regulatory cells activity, and it seems
to be a cause for recurrence of the clinical symptoms [15].
The destruction caused by MS is usually on the myelin of basal gan-
glia [16], brainstem [17] and spinal cord [18]. Destroying white matter
can lead to low pace of transfer of information to the processing areas.
According to the placewhich the destructions happenedwe can see dif-
ferent kinds of clinical disorders.
Primarily MS is an inﬂammatory disorder as a consequence of a local
lymphocyte inﬁltration [19] and this can damage the myelin and even
the axons [20]. These damaged parts could be recovered but the recoveries
are not stable [21]. In otherwords oligodendrocyteswhich are responsible
for production and maintenance of myelin, have been destroyed by auto-
antibodies and the outcome is destruction of the axons [22], because
they aremuchmore vulnerable than before due to the absence of themy-
elin. Axons demolition can be an inducement for the Astrocytosis (also
called as Astrogliosis), an abnormal increase in the amount of astrocytes
[23].
The inﬂammatory response is a reason for releasing different kinds of
cytokines and autoantibodies and this can cause more destruction inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tokines and proteins. As we know one role of BBB is not to let entrance of
T cells to central nervous system (CNS), but sometimes because of some
previous infections some T cells can ﬁnd a way to CNS and remain there
even after getting cleaned of infection agents and be a reason for future
problems [24–26]. Such immune responses and cytokines also induce ap-
optosis (programmed cell death) in CNS [27–30]; this apoptosis can be in-
tensify complications ofMS [14,31]. Since neurodegeneration occurs after
demyelination, apoptosis of the nerve cells is recently approvedwith bet-
ter evidences than before [32].
Killer-cells immunoglobulin-like receptors (KIRs) are one of the
markers on surface of NKs, and like HLAs, they are inherited as the form
of haplotypes. KIR has 14 genes and 2 pseudo-genes which 8 of them
are of the inhibitors and 6 of them are activators. KIRs which are
expressed on the surface of NKs interact with HLA class I on surface of
the other nuclear cells of human. The result of this interaction is the im-
mune tolerance if their targeted cells are healthy, and cytotoxic activity
of NKs against the cancerous targeted cells of theirs. According to the
fact that HLA is the most polymorphic loci in human genome and also
KIR has different types of genes and alleles for each gene, different inter-
actions of KIR-HLA can be along with susceptibility to different diseases
like cancers among different ethnicities and populations; this is called as
“disease association” in medical anthropology. Some of these 14 genes
are seems to be associated as risk factors with some cancers while the
other ones are known for their protective effects [13,33–42].
Since NKs play key roles in immune tolerance and on the other hand
KIRs are of their functional surface molecules, we intend to perform a
meta-analysis for the correlation of KIR genes and MS.
2. Methods
As our search strategy in the current meta-analysis, we used the
meta-search engines Pubmed, Google scholar and Researchgate. OurFig. 1. KIR inhibitory genes. The favours A shows protectkey word was KIR AND “multiple sclerosis” in titles. Finally we found
ﬁve articles. Among them 3 articles of those found in google scholar
seemed to be fake! Because their bibliography was for the journals tis-
sue antigens and European journal of neurology, but we couldn't trace
them in web site of these journals. Therefor only two studies were
used for our meta-analysis. Both of them had been published in Journal
of neuroimmunology.
We used the software comprehensive meta-analysis version 2 for
ﬁnal analyses. The test Chi-squared 2multiplied by 2with Yate's correc-
tion was staffed for each gene. Totally there were the informations of
568 MS patients and 280 controls.
3. Results
Based on the results of our meta-analysis KIR2DS1 seems as a protec-
tive factor forMSdisease. Fusco et al. [43] believed that differentKIR genes
may affect both susceptibility and resistance to such autoimmune disor-
ders that their pathogenesis in MS is still unclear. They found a possible
protective role of the activating gene KIR2DS1, enhanced in the presence
of its ligand group HLA-C2. In their belief, the presence of such KIRs ac-
companied by their HLA ligands results in the immunomodulatory func-
tion of NKs [43]. Bettencourt et al. [44] believed that KIR genes may
inﬂuence both susceptibility and resistance toMS. They observed a nega-
tive association between the activating gene KIR2DS1 and MS indepen-
dently from the presence of HLA-DRB1*15 allele. They believed that this
activating KIR seems to play a protection role against MS via modulation
of autoreactive T cells byNKs [44]. The results of themeta-analyses for the
inhibitory and activating genes are shown respectively in Figs. 1 and 2.
4. Discussion
NKs are a part of innate lymphoid cells (ILCs) and they have CD3-
phenotype generally and also have 2 subsets, CD56bright and CD56diming effect and the B shows the genes as risk factors.
Fig. 2. KIR activating genes. The favours A shows protecting effect and the B shows the genes as risk factors.
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in blood, peripheral organs and secondary lymphoid organs. Most NKs
are CD56dim and only about 10% of them are the CD56bright which
have regulatory roles in immune system whereas CD56dims are mostly
act in cytotoxicity [10–13]. NKs have a variety of roles in MS; their ma-
turity which is in CNS and their engagement with different kinds of re-
ceptors in neural cells, seem to result a correlationwithMS. For instance
they have some receptors like the CX3CR1 which is more expressed in
relapse phase of MS than the stable phase. As another example, a de-
crease in NK population can cause more attacks in relapse phase of the
disease. NK activity regulates with different kinds of receptors that
help them to recognize their targets; for example the KIR system
works with lectin-like NKG2 receptors to modulate immune response.
KIRs are divided into two groups, one the inhibitory which their ligands
are usually HLA class 1molecules and the other group is the stimulatory
with unknown ligands. According to some researches, there is a signiﬁ-
cant correlation between KIRs and their HLA ligands activity with MS
disease. In some patients a signiﬁcant deﬁcit of HLA BW4 were found,
this reduction in the amount of HLABW4 can inﬂuence NK activity and
cause a diminished response to infectious disease and increased suscep-
tibility to MS. Some in vitro studies also show that NKs can cause tissue
injury in MS because they can directly lyse neural tissues [45–47].
KIR2DS1 based on the results of ourmeta-analysis seemsas a protec-
tive factor for MS disease, contrary to what had been expected; because
we anticipated that these receptors were considered as a risk factor for
this type of inﬂammation-related disease.
The followings can be considered as reasons to justify this contradic-
tion: First, MS is a disease caused by hypersensitivity type IV or cell-me-
diated immune responses, and not by inﬂammation. Inﬂammation is
just a cause for progression and recurrence of the disease. Second,
KIRs have different effects in combinationwith different ligands. For ex-
ample, it may be something entirely different in result if KIR combined
with different types of HLA. Lack of former studies about this issueand also lack of studies on other molecules like CD94 and NKG2a are
of the limitations of ours in this paper. It is worth noting that these re-
ceptors are more abundant in healthy groups compared with patients
but this does not mean that the lesser amount of these receptors is a
risk factor for the disease. Third, the reasoning of Fusco et al. and
Bettencourt et al.mentioned above, could be good responses to this con-
tradiction in turn. Forth, as we mentioned in introduction, NKs ﬁght
with autoreaction of T cells [14]; hence the activation of NKs through ac-
tivating KIRs like 2DS1 can impede the autoreaction [44].
5. Conclusions
Among the 14 genes of KIR in the human genome, lack of the activat-
ing gene KIR2DS1 is accompanied by MS. No KIR gene found to be a risk
factor for MS. Further studies on other molecules of NKs like CD94 and
NKG2a is suggested.
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